Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens

Douglas J. Hartman, Alyssa M. Krasinskas, Shikhar Uttam, Kevin Staton, Rajan Bista, Sumera Rizvi, Adam Slivka, Randall Brand, Yang Liu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: The accurate diagnosis of malignancy from small bile duct biopsy specimens is often challenging. This proof-of-concept study assessed the feasibility of a novel optical technology, spatial-domain low-coherence quantitative phase microscopy (SL-QPM), that assesses nanoscale structural alterations in epithelial nuclei for improving the diagnosis of malignancy in bile duct biopsy specimens. Methods: The SL-QPM analysis was performed on standard histology specimens of bile duct biopsy specimens from 45 patients. We analyzed normal cells with benign follow-up, histologically normal cells with pancreaticobiliary malignancy, and malignant epithelial cells. Results: The SL-QPM-derived nuclear nanomorphology marker can not only distinguish benign and malignant epithelial cells but can also detect features of malignancy in those cells normal by light microscopy with a discriminatory accuracy of 0.90. When combining pathology with SL-QPM, the sensitivity is improved to 88.5% from 65.4% of conventional pathology, while maintaining 100% specificity. Conclusions: SL-QPM-derived nuclear nanomorphology markers represent a novel approach for detecting malignancy from histologically normal-appearing epithelial cells, with potential as an adjunctive test in patients with negative or inconclusive pathologic diagnosis on bile duct biopsy specimens.

Original languageEnglish (US)
Pages (from-to)884-891
Number of pages8
JournalAmerican journal of clinical pathology
Volume141
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Bile Ducts
Nuclear Microscopy
Microscopy
Biopsy
Epithelial Cells
Neoplasms
Pathology
Feasibility Studies
Histology
Technology
Light

Keywords

  • Gastrointestinal
  • Molecular diagnostics
  • Technique

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens. / Hartman, Douglas J.; Krasinskas, Alyssa M.; Uttam, Shikhar; Staton, Kevin; Bista, Rajan; Rizvi, Sumera; Slivka, Adam; Brand, Randall; Liu, Yang.

In: American journal of clinical pathology, Vol. 141, No. 6, 01.01.2014, p. 884-891.

Research output: Contribution to journalArticle

Hartman, Douglas J. ; Krasinskas, Alyssa M. ; Uttam, Shikhar ; Staton, Kevin ; Bista, Rajan ; Rizvi, Sumera ; Slivka, Adam ; Brand, Randall ; Liu, Yang. / Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens. In: American journal of clinical pathology. 2014 ; Vol. 141, No. 6. pp. 884-891.
@article{e86431f4a15643d4aadb90b10906f02c,
title = "Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens",
abstract = "Objectives: The accurate diagnosis of malignancy from small bile duct biopsy specimens is often challenging. This proof-of-concept study assessed the feasibility of a novel optical technology, spatial-domain low-coherence quantitative phase microscopy (SL-QPM), that assesses nanoscale structural alterations in epithelial nuclei for improving the diagnosis of malignancy in bile duct biopsy specimens. Methods: The SL-QPM analysis was performed on standard histology specimens of bile duct biopsy specimens from 45 patients. We analyzed normal cells with benign follow-up, histologically normal cells with pancreaticobiliary malignancy, and malignant epithelial cells. Results: The SL-QPM-derived nuclear nanomorphology marker can not only distinguish benign and malignant epithelial cells but can also detect features of malignancy in those cells normal by light microscopy with a discriminatory accuracy of 0.90. When combining pathology with SL-QPM, the sensitivity is improved to 88.5{\%} from 65.4{\%} of conventional pathology, while maintaining 100{\%} specificity. Conclusions: SL-QPM-derived nuclear nanomorphology markers represent a novel approach for detecting malignancy from histologically normal-appearing epithelial cells, with potential as an adjunctive test in patients with negative or inconclusive pathologic diagnosis on bile duct biopsy specimens.",
keywords = "Gastrointestinal, Molecular diagnostics, Technique",
author = "Hartman, {Douglas J.} and Krasinskas, {Alyssa M.} and Shikhar Uttam and Kevin Staton and Rajan Bista and Sumera Rizvi and Adam Slivka and Randall Brand and Yang Liu",
year = "2014",
month = "1",
day = "1",
doi = "10.1309/AJCPXQD0NSJNK0CX",
language = "English (US)",
volume = "141",
pages = "884--891",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "6",

}

TY - JOUR

T1 - Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens

AU - Hartman, Douglas J.

AU - Krasinskas, Alyssa M.

AU - Uttam, Shikhar

AU - Staton, Kevin

AU - Bista, Rajan

AU - Rizvi, Sumera

AU - Slivka, Adam

AU - Brand, Randall

AU - Liu, Yang

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: The accurate diagnosis of malignancy from small bile duct biopsy specimens is often challenging. This proof-of-concept study assessed the feasibility of a novel optical technology, spatial-domain low-coherence quantitative phase microscopy (SL-QPM), that assesses nanoscale structural alterations in epithelial nuclei for improving the diagnosis of malignancy in bile duct biopsy specimens. Methods: The SL-QPM analysis was performed on standard histology specimens of bile duct biopsy specimens from 45 patients. We analyzed normal cells with benign follow-up, histologically normal cells with pancreaticobiliary malignancy, and malignant epithelial cells. Results: The SL-QPM-derived nuclear nanomorphology marker can not only distinguish benign and malignant epithelial cells but can also detect features of malignancy in those cells normal by light microscopy with a discriminatory accuracy of 0.90. When combining pathology with SL-QPM, the sensitivity is improved to 88.5% from 65.4% of conventional pathology, while maintaining 100% specificity. Conclusions: SL-QPM-derived nuclear nanomorphology markers represent a novel approach for detecting malignancy from histologically normal-appearing epithelial cells, with potential as an adjunctive test in patients with negative or inconclusive pathologic diagnosis on bile duct biopsy specimens.

AB - Objectives: The accurate diagnosis of malignancy from small bile duct biopsy specimens is often challenging. This proof-of-concept study assessed the feasibility of a novel optical technology, spatial-domain low-coherence quantitative phase microscopy (SL-QPM), that assesses nanoscale structural alterations in epithelial nuclei for improving the diagnosis of malignancy in bile duct biopsy specimens. Methods: The SL-QPM analysis was performed on standard histology specimens of bile duct biopsy specimens from 45 patients. We analyzed normal cells with benign follow-up, histologically normal cells with pancreaticobiliary malignancy, and malignant epithelial cells. Results: The SL-QPM-derived nuclear nanomorphology marker can not only distinguish benign and malignant epithelial cells but can also detect features of malignancy in those cells normal by light microscopy with a discriminatory accuracy of 0.90. When combining pathology with SL-QPM, the sensitivity is improved to 88.5% from 65.4% of conventional pathology, while maintaining 100% specificity. Conclusions: SL-QPM-derived nuclear nanomorphology markers represent a novel approach for detecting malignancy from histologically normal-appearing epithelial cells, with potential as an adjunctive test in patients with negative or inconclusive pathologic diagnosis on bile duct biopsy specimens.

KW - Gastrointestinal

KW - Molecular diagnostics

KW - Technique

UR - http://www.scopus.com/inward/record.url?scp=84904488904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904488904&partnerID=8YFLogxK

U2 - 10.1309/AJCPXQD0NSJNK0CX

DO - 10.1309/AJCPXQD0NSJNK0CX

M3 - Article

C2 - 24838334

AN - SCOPUS:84904488904

VL - 141

SP - 884

EP - 891

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 6

ER -